Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Relevant post - Let’s all hope that with the Internet tool, the days of “turn a blind eye” and “don’t look behind the curtain” are coming to an end.
Adam....
Surely, as a PR person you would know that you can't bastardize someone's work!
Yes, Austin, that was the news. All gone. Bye - thanks for coming
DC-Vax has been granted orphan drug status by FDA - the intention being to help a new drug navigate clinical processes, and, if successful, come to market with a bit of assistance. An important feature of the orphan status is allowing a 7-year market exclusivity to “first of their type to reach the market” enabling the company to recoup drug development costs. Why are we witnessing disturbing activity sabotaging and overriding the very spirit of this government initiative and why does it continue unaddressed?
I am stymied as to why a government initiative is implemented with noble objectives in mind only to have it deliberately ravaged for self-enriching purposes in the public marketplace. Further, how is it that a self-serving blogger outweighs the IOM (Institute of Medicine) leadership opinion?
Am I overthinking this - the tail wagging the dog? I’m in the waiting room with the rest of you longs.
I read Mr. Feuerstein’s article and wondered if there were contributing authors. I’m sure if we ask, he would be happy to share the names and their appropriate standing in the immuno-oncology world. After all, they should receive due credit for authorship.
Doc Logic
I think you have misinterpreted my response to md1225’s post 75072.
BP advertising monies are huge to media; BP is most likely going to be negatively affected by NWBO’s disruptive technology; BP money = BP influence. Is the media going to carry a non-revenue story, even if it is a great story, and upset their MFN clients? Business sense would say, “No.”
If a partnership is announced with BP, well then things will change. These remarks are my personal opinions of course.
Sorry I wasn’t more succinct first time around. I do enjoy your in-depth knowledge of the science.
Are you referring to media interest and coverage? Here’s an interesting stat to take into consideration:
Media revenue:
More drugs have come to mean more DTC advertising. And, 2015 was a record year for both.
Pharma spent $5.17 billion on direct-to-consumer advertising last year, according to Nielsen's calculations, nearing the previous pinnacle of $5.4 billion set in 2006. That's a 14.9% increase over the $4.5 billion spent in 2014, capping three years of DTC ad gains since a low of $3.4 billion in 2012. (FiercePharma - Mar 2016)
Media revenue stream from Pharma (see above)
NWBO has yet to be a paying client
Their time in the sun is coming, I'm sure!
A component of Bosch's presentation:
• Full course of DCVax® doses can be manufactured in a single batch within about a week, and can be stored frozen until needed (including for years).
What are the chances to have LP's HealthBank introduced here. Perhaps that facility will be located on the Sawston property for European location.
I hope your post isn't a response to the spelling of skeptical/sceptical because sceptical is proper outside North America; skeptical is the common spelling within North America.
In support of your post though, I agree that some of our members here would be severely reprimanded by their English teachers for not having a command of the King's English.
I think the disappointment in Larry Smith’s latest is a bit harsh as he has been an authentic supporter of NWBO for quite some time. He may have wanted to step-up-to-the-plate to provide a relief from the imposed silence and unrelenting attacks - a catharsis, and he may have published in more haste than usual. I thank him for his efforts.
My own curiosity is peaked as Baker Brothers held a substantial position in Synageva and Synageva was acquired by Alexion last year. I believe BB now has a sizable position in Alexion.
http://www.bloomberg.com/news/articles/2015-05-06/baker-brothers-hedge-fund-gets-1-4-billion-on-takeover
Baker Brothers Advisors
Infographic 2015 Clinical News provided by Robert Margolin, VP Corporate Development, Cognate Bioservices in collaboration with Immunotherapy Forum
http://www.immunotherapyforum.com/__media/Files/Clinical-news-in-2015-PART-I.pdf
I know we are all anxious for the investigation to be completed; however, the statement in the 12/8/2015 PR stated, “The Special Committee anticipates that the investigation will get under way in the coming week and will likely take at least 90 days.”
There was no definitive time stated.
Quote:
"I believe the investigation has not been revealed because it is doing something of greater value than a short term name clearing for the NWBO management team, given the background of the investigators, and, that will be wonderful for all real investors."
I agree with you....
IMO the investigation will provide evidentiary support of malfeasance in regard to NWBO as the obvious intent was to prevent this small cap company from attracting capital support and industry/public recognition. I doubt specific “names,” whether they be competitors, hedge funds, shorts, naked shorts, etc., will become public as NWBO will become a player in the pharma sandbox and all involved must move on to play together. I am of the opinion, and very hopeful, that the investigative findings will lay the groundwork for legislation designed to curtail current malicious and destructive practices and NWBO will be an example, a poster-child if you will, of the willful damage done to new innovative companies.
Indeed!
I just recently read an article on Dr. Reardon
http://www.ascopost.com/issues/july-10-2016/expert-point-of-view-david-reardon-md/
New SEC filings....Amendment to Prospectus
Filed 8.26.2016
https://www.sec.gov/cgi-bin/browse-edgar?company=Northwest+Biotherapeutics&owner=exclude&action=getcompany
I salut your courage.
Well Buddy, I just don’t know. Here they (Cognate) are placing their little ole company as a Gold Sponsor with about 850 senior executives of their industry planning on attending this event, I just don’t get it.
From Immunotherapy World website re upcoming January 2017 conference in Miami:
“2015 was a bumper year for the cell, gene and immunotherapy sectors. Before we look ahead to 2016, we thought it would first be good to reflect on the past 12 months of deals and collaborations, regulatory changes and clinical successes from across the regenerative medicine sphere.
In partnership with Robert Margolin, Vice President of Corporate Development, Cognate Bioservices Inc using the data that he has collected over 2015, we are pleased to share them with you now:”
http://www.immunotherapyforum.com/page.cfm/link=166
Per chance geology....you know, a passion for digging up dirt
Quote:
“Big Pharma is interested in the technology"
It’s interesting to note that the 2017 Immunotherapy World event will be in Miami (January 17-20, 2017) this time around.
Cognate is listed as a Gold Sponsor
On the second day’s agenda, (January 19th, following the “Japan Partnering Breakfast”) is listed:
Immuno-oncology combination therapy strategy (parts 1 & 2)
I don’t share your sentiments on this: The findings of the investigation may add supportive evidence to set a foundation for guidelines and/or legislation to curb nefarious activity designed to unfairly enrich others or deliberately harm a disruptive competitor. NWBO is not the only victim targeted by misdeeds!
Quote:
"As far as the news release about their internal and external investigations maybe, just maybe there is something much bigger going on behind the scenes and so they wait out both investigations perhaps at the behest of investigators. Could it be possible that the recent changes in law towards states rights might be the impetus for bringing a case against protagonists of small biotech's?"
BINGO!
On ASCO website:
“In a special session on Monday afternoon, June 6, Vice President Joe Biden will deliver remarks on the Cancer Moonshot Initiative to accelerate cancer research, prevention, treatment, and care.
http://am.asco.org
Moonshot advisory board:
https://www.statnews.com/2016/04/04/cancer-moonshot-panel/
Support in high places:
(Name removed) says:
March 10, 2016 6:36 pm
Mr. Woodford, as a globally respected financial figure, would you support stronger US legislation designed to protect small, innovative and disruptive companies (particularly biotech) seeking capitalization, from falling victim to manipulation devised to harm their chances of success and/or to enrich the pockets of manipulators due to nefarious activities?
Reply
NEIL WOODFORDMODERATOR says:
March 15, 2016 2:56 pm
Yes, (name removed,) that sounds sensible. Kind regards Neil
You “figured” us guys out long ago? You only made an appearance here on April 10th with your “Hello Board” greeting. By the way - you didn’t have us at HELLO as you were the one quickly figured out.
Vator.....Your quote
"The cost has been lost market cap and the ability to raise money at a reasonable price."
I do not have a legal background; however, I recollect a term called “tortious interference “ attributed to intent to do harm - any attorneys in the room.
Well, it's good and quite costly that's why I'm long in NWBO
I firmly believe that NWBO will have a leading position in Biden's Moonshot. Comments from last Friday's speech at the Vatican:
“Our goal in the U.S. is to do in the next five years what would otherwise take a decade, but that’s the work of all of us,” he said, and he called for “an international commitment” to eliminating cancer and deaths related to the disease. National Catholic Register, May 1, 2016
You guys are really reaching today. Often times some of the naysayer posts were a bit nasty; however, the last few days, particularly today, the posts have crossed the line into the humorous arena. I think the entertainment industry calls it, “jumping the shark.”
http://www.nwbio.com/contact-us/
Sign up at bottom of page for emails
Absence of media coverage and attention - IMO, I would apply the Pareto Principle
“… this rule says that 20% of your activities will account for 80% of your results. 20% of your customers will account for 80% of your sales. 20% of your products or services will account for 80% of your profits. 20% of your tasks will account for 80% of the value of what you do, and so on. ……Pareto noticed that people in his society seemed to divide naturally into what he called the ‘vital few,’ the top 20% in terms of money and influence, and the “trivial many,” the bottom 80%”
(Leadership Success/Brian Tracy International)
It’s interesting to take note of the advertising revenue dollars flowing into the media by the pharmaceutical industry. One doesn’t really need to do research on this as any TV viewer will note that pharmaceutical ads dominate. Let’s see BP advertising and marketing dollars $millions; NWBO advertising and marketing dollars $0.
I’ll leave it at that; you all can connect the dots I’m sure.
Recap of V.P. Biden’s speech to AACR attendees today
http://www.dddmag.com/articles/2016/04/biden-urges-cancer-researchers-collaborate-calls-guidance
Thanks for the follow up; I was at a lecture this afternoon and unable to join the webcast. I agree with you - this is great!
Vice President Biden and Dr. Jill Biden to address AACR attendees today at 12:15 pm.
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=63&DetailItemID=484#Webcast